Semax Peptide Research: 7 Key Findings on BDNF and Neurological Signalling
Exploring the ACTH-derived heptapeptide, neurotrophin gene expression, melanocortin biology, experimental brain injury models and the limits of human clinical evidence.
Semax peptide research focuses on a synthetic seven-amino-acid peptide developed from a fragment of adrenocorticotropic hormone (ACTH). Unlike the full-length hormone, Semax was designed to retain selected neurological activities associated with ACTH-derived sequences while avoiding conventional corticotropic hormonal effects.
Semax has attracted scientific interest because experimental studies have reported changes in brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), neurotrophin receptor signalling and gene-expression patterns in the nervous system.
Several influential studies were conducted in Russian research institutions during the early 2000s. They demonstrated that Semax could alter neurotrophin-related measurements in cultured rat glial cells and specific brain regions in animal models. Semax peptide research
One 2006 study reported increased hippocampal BDNF protein levels and changes in TrkB receptor phosphorylation following Semax exposure in rats. Other investigations found that the direction and timing of neurotrophin gene-expression changes depended on the brain region examined.
These results provide a basis for studying Semax in neurological signalling, synaptic plasticity and experimental responses to cerebral ischaemia. Semax peptide research
However, changes in BDNF expression in rats do not establish improved memory, neuroprotection or cognitive performance in humans.
Semax has been used clinically in Russia, but the human evidence base remains limited by study design, geographical concentration and incomplete independent replication. It is not an FDA-approved medicine in the United States. Semax peptide research
This guide examines seven major scientific findings, the mechanisms researchers have proposed and the analytical considerations needed for reliable Semax laboratory research.
1. What Is Semax? Structure, Sequence and ACTH Origins
Semax is a synthetic heptapeptide consisting of seven amino acid residues. Semax peptide research
Its commonly reported sequence is:
Met–Glu–His–Phe–Pro–Gly–Pro
In single-letter amino acid notation:
MEHFPGP
Semax Molecular Characteristics
| Property | Scientific description |
|---|---|
| Compound | Semax |
| Amino acid length | 7 residues |
| Sequence | Met–Glu–His–Phe–Pro–Gly–Pro |
| Single-letter sequence | MEHFPGP |
| Approximate molecular mass | 813.9 Da for the unmodified peptide |
| Molecular formula | C₃₇H₅₁N₉O₁₀S |
| Structural origin | Modified analogue of ACTH(4–10) |
| Principal research areas | Neurotrophin signalling, gene expression, experimental neuroprotection and neurological biology |
| US regulatory status | Not FDA-approved |
These molecular specifications describe the conventional Semax sequence. Salt forms, modified derivatives and formulated products may require different analytical specifications. Semax peptide research
What Is ACTH?
Adrenocorticotropic hormone is a peptide hormone derived from proopiomelanocortin, or POMC.
It is best known for its role in stimulating adrenal steroid production through melanocortin receptor signalling.
However, ACTH and its fragments have also been studied for neurological and behavioural effects. Semax peptide research
How Was Semax Developed?
Semax was designed using the N-terminal four residues of the ACTH(4–10) fragment, followed by a Pro–Gly–Pro sequence.
The original ACTH(4–10) fragment contains:
Met–Glu–His–Phe–Arg–Trp–Gly
Semax instead contains:
Met–Glu–His–Phe–Pro–Gly–Pro
This modification changes the peptide’s structure and potentially its interactions with biological targets. Semax peptide research
Why Add Pro–Gly–Pro?
The C-terminal Pro–Gly–Pro segment was incorporated partly to influence the peptide’s susceptibility to enzymatic degradation. Semax peptide research
However, increased stability relative to another sequence does not establish a particular shelf life or stability profile for every Semax formulation.
Is Semax the Same as ACTH?
No.
Semax shares a sequence region with ACTH but is a distinct synthetic peptide.
Its effects should not be assumed to reproduce the hormonal activity of full-length ACTH.
Is Semax the Same as N-Acetyl Semax Amidate?
No.
N-acetylated or amidated derivatives are chemically modified compounds.
Their molecular masses, stability characteristics and pharmacological behaviour may differ from those of the original Semax sequence.
Research involving a modified analogue should not automatically be attributed to unmodified Semax.
2. Semax Peptide Research and BDNF Gene Expression
One of the most frequently cited findings in Semax peptide research concerns BDNF.
BDNF stands for brain-derived neurotrophic factor.
It is a signalling protein involved in neuronal development, synaptic function and activity-dependent plasticity. Semax peptide research
What Does BDNF Do?
BDNF participates in processes including neuronal survival, synaptic modification and the regulation of neural circuits.
Its effects depend on the cellular environment, developmental stage and receptor systems involved.
The 2001 Glial Cell Study
Researchers examined Semax in cultures of rat glial cells derived from the basal forebrain.
They measured messenger RNA associated with BDNF and NGF.
The study reported rapid changes in neurotrophin gene expression.
At a particular experimental time point, the researchers observed substantial increases in BDNF and NGF messenger RNA relative to controls.
Why Glial Cells Matter
Glial cells support numerous functions in the nervous system.
They participate in metabolic regulation, communication with neurons and responses to tissue stress.
Their role extends beyond passive structural support.
Does Increased BDNF mRNA Mean Increased BDNF Protein?
Not necessarily.
Messenger RNA is an intermediate involved in protein synthesis.
A change in transcript abundance does not guarantee an identical change in protein concentration.
The 2006 Rat Hippocampus Study
A study published in Brain Research investigated Semax-associated changes in the rat hippocampus.
The researchers reported a maximum approximately 1.4-fold increase in BDNF protein and a 1.6-fold increase in TrkB phosphorylation under their experimental conditions.
They also observed changes in BDNF and TrkB messenger RNA.
What Is the Hippocampus?
The hippocampus is a brain structure involved in several forms of learning and memory.
It is also important in research concerning neural plasticity and responses to neurological injury. Semax peptide research
What Can Be Concluded?
The study provides evidence that Semax can influence BDNF-related signalling measurements in the rat hippocampus. Semax peptide research
It does not establish that Semax improves memory in healthy humans.
3. Semax and TrkB: Neurotrophin Receptor Signalling
BDNF acts through receptor systems, including tropomyosin receptor kinase B, commonly abbreviated TrkB.
TrkB is a receptor tyrosine kinase. Semax peptide research
What Happens When BDNF Activates TrkB?
BDNF binding can trigger receptor-related phosphorylation and downstream signalling.
These processes influence neuronal responses through several intracellular pathways.
Why TrkB Phosphorylation Matters
Phosphorylation is a chemical modification that can change the activity or interactions of proteins.
Researchers frequently measure receptor phosphorylation as an indicator of signalling activity.
What Did the 2006 Study Show?
The researchers observed increased TrkB phosphorylation in the rat hippocampus following Semax exposure.
This finding accompanied changes in BDNF protein measurements. Semax peptide research
Does Semax Directly Bind TrkB?
The findings do not establish Semax as a direct TrkB receptor agonist.
An increase in TrkB phosphorylation could result from changes in BDNF availability or other upstream events.
What About Semax Binding Sites?
A separate 2006 study investigated binding of radiolabelled Semax to membranes from the rat basal forebrain.
The researchers reported specific, reversible and calcium-dependent binding under the tested conditions. Semax peptide research
Was the Molecular Receptor Identified?
Those binding results supported the presence of Semax-associated binding sites.
They did not conclusively identify a single molecular receptor responsible for every reported effect.
Why Receptor Identification Matters
Binding to a tissue preparation is not equivalent to identifying a purified receptor.
Additional experiments are needed to determine molecular identity, binding selectivity and functional consequences.
Does Semax Act Through Melanocortin Receptors?
Its ACTH-derived structure makes melanocortin biology relevant.
However, Semax should not automatically be classified as a conventional ACTH-like melanocortin receptor agonist.
The complete receptor-level mechanism remains incompletely characterised.
Scientific Interpretation
Semax-associated changes in BDNF and TrkB signalling provide a plausible mechanism for further neurological research.
They are not proof of a clinically meaningful cognitive benefit. Semax peptide research
4. Semax, NGF and Brain-Region-Specific Gene Expression
NGF stands for nerve growth factor.
Like BDNF, it belongs to the neurotrophin family.
What Does NGF Do?
NGF contributes to the development, maintenance and function of selected neuronal populations.
It acts through receptor systems including TrkA and p75NTR. Semax peptide research
The 2007 Gene Expression Study
Researchers examined BDNF and NGF gene expression in several regions of the rat brain following Semax exposure.
The results were not uniform.
In the hippocampus, both neurotrophin-related transcripts increased under the reported experimental conditions.
In other brain regions, the direction of change differed. Semax peptide research
What Happened in the Frontal Cortex?
The study reported reduced NGF gene expression in the frontal cortex at a particular time point.
This contrasts with the increases reported in the hippocampus.
Why This Matters
It demonstrates that Semax-associated neurotrophin responses may be region-specific.
A statement that Semax simply increases BDNF and NGF throughout the brain would misrepresent the evidence.
The 2008 Time-Course Study
A later investigation examined changes in BDNF and NGF expression at different time points.
The researchers observed that expression patterns changed over time and differed between brain regions.
Why Timing Matters
Gene-expression responses can be transient. Semax peptide research
A measurement collected at one time point may differ substantially from a measurement collected later.
What About the Retina?
Additional research examined neurotrophin gene expression in the retina alongside brain tissues.
These experiments further demonstrated the importance of tissue-specific interpretation. Semax peptide research
Is More BDNF Always Better?
No.
BDNF participates in complex signalling networks.
Its effects depend on the tissue, timing, receptor distribution and physiological context. Semax peptide research
A higher BDNF measurement is not automatically a universal indicator of improved neurological function.
Research Implications
Semax studies should consider both spatial and temporal differences in neurotrophin signalling.
This is particularly important when comparing findings across experimental models. Semax peptide research
5. Semax Research in Cerebral Ischaemia and Neuroprotection
Cerebral ischaemia occurs when blood supply to part of the brain becomes insufficient.
It can produce complex changes involving oxygen availability, cellular metabolism, inflammation and neuronal injury.
Why Study Peptides in Ischaemia?
Peptides can serve as experimental tools for examining signalling pathways involved in injury responses.
Semax has been investigated in animal models of cerebral ischaemia.
What Have Animal Studies Reported?
Some studies reported changes in neurological outcomes, tissue injury measurements and gene-expression patterns following Semax exposure.
These findings motivated further research into its potential neuroprotective mechanisms. Semax peptide research
What Is Neuroprotection?
Neuroprotection generally refers to processes that reduce neuronal injury or preserve neural function under damaging conditions.
However, the term is often used broadly. Semax peptide research
A reduction in one experimental injury marker does not establish comprehensive neuroprotection.
Gene Expression After Ischaemia
Experimental cerebral ischaemia can alter the expression of many genes.
Researchers have examined whether Semax modifies some of these responses.
Why Transcriptomic Findings Need Careful Interpretation
Transcriptomic analysis measures gene-expression patterns across many genes.
It can identify associations and generate mechanistic hypotheses. Semax peptide research
However, a gene-expression change does not necessarily establish improved tissue function.
Does Semax Treat Human Stroke?
The available evidence does not justify treating Semax as a proven stroke treatment under US or UK clinical standards.
Although clinical studies have been reported, many are limited by incomplete information about randomisation, blinding, controls and reproducibility. Semax peptide research
Why Human Trials Matter
Stroke outcomes are influenced by numerous factors, including the type and severity of injury and the timing of established medical care.
Reliable treatment conclusions require appropriately controlled human trials measuring meaningful clinical outcomes. Semax peptide research
Important Distinction
Preclinical neuroprotection is not equivalent to demonstrated human stroke recovery.
Experimental findings should not be used to delay or replace established emergency stroke treatment.
6. Semax, Learning, Memory and Cognitive Research
Semax is often discussed as a nootropic peptide.
The term nootropic is commonly used for substances proposed to influence cognition.
However, it is not itself proof of clinical effectiveness.
What Have Animal Studies Examined?
Researchers have investigated Semax in behavioural experiments involving learning, memory and conditioned responses.
Some studies reported changes in task performance.
The 2006 Hippocampal Study
The study linking Semax with BDNF and TrkB signalling also reported changes in conditioned avoidance responses.
This provided a possible connection between molecular measurements and behavioural outcomes.
Why Behavioural Assays Are Difficult to Interpret
Performance in an animal task can be influenced by several factors.
These may include movement, stress, motivation, sensory function and learning.
A change in task performance does not necessarily indicate a specific improvement in memory.
What About Human Attention?
Some clinical reports have examined attention or cognitive outcomes in neurological settings.
However, the evidence base is not sufficiently robust to establish general cognitive enhancement in healthy adults.
Can BDNF Explain Every Cognitive Effect?
No.
BDNF is involved in several neural processes, but cognition emerges from complex interactions among brain regions and signalling systems.
A change in one molecular marker cannot fully explain behavioural performance.
What About Healthy Students or Workers?
There is insufficient high-quality clinical evidence to conclude that Semax improves learning, concentration or productivity in healthy individuals.
What About Long-Term Cognitive Effects?
Long-term safety and effectiveness remain inadequately characterised.
Short-term experimental findings should not be extrapolated into claims about sustained cognitive improvement.
Scientific Interpretation
Semax provides an interesting model for studying relationships between neurotrophin signalling and behaviour.
Its use as a general cognitive enhancer is not supported by strong, independently replicated clinical evidence.
7. Semax Human Evidence, Safety and Regulatory Status
Semax has a more extensive history of clinical use in Russia than many experimental peptides discussed in research catalogues.
Nevertheless, regulatory use in one country does not establish approval or equivalent clinical evidence in another.
Is Semax Approved in the United States?
No.
Semax is not an FDA-approved medicine.
Has Semax Been Used Clinically in Russia?
Yes.
Semax has been developed and used in Russia for certain neurological indications.
However, those uses should be distinguished from the regulatory standards and approved indications of other countries.
What Does the Human Literature Show?
The published human literature includes studies involving neurological conditions and rehabilitation.
Some reports describe favourable outcomes.
However, important limitations include small samples, incomplete methodological reporting and limited independent replication.
Does Clinical Use Prove Effectiveness?
No.
Clinical use and regulatory authorisation are relevant historical facts, but they do not automatically establish efficacy for every proposed application.
What Did the FDA Review in 2026?
FDA scientific materials prepared for the July 2026 Pharmacy Compounding Advisory Committee meeting examined Semax as a bulk drug substance.
The review discussed nonclinical pharmacology and gaps in the evidence supporting human use.
Why Safety Data Matter
A compound may produce measurable effects in animal models while still having an incompletely characterised human safety profile.
Potential concerns can include adverse reactions, immunogenicity, impurities and formulation-related risks.
What Is Immunogenicity?
Immunogenicity refers to the ability of a substance to provoke an immune response.
It is one consideration in evaluating peptide-based pharmaceutical materials.
Are All Semax Formulations Equivalent?
No.
Differences in concentration, excipients, chemical form, manufacturing quality and stability can affect product characteristics.
A laboratory research material should not be considered equivalent to a clinically studied pharmaceutical formulation merely because it shares the name Semax.
The Evidence Boundary
Semax has scientifically interesting preclinical findings and a history of clinical research.
However, the available evidence does not establish it as a broadly effective or FDA-approved neurological treatment.
Semax Peptide Research: Evidence Strength by Application
| Research area | Evidence available | Scientific interpretation |
|---|---|---|
| ACTH-derived sequence | Established chemical identity | Semax is a modified ACTH-fragment analogue |
| BDNF gene expression | Rat glial cell and brain studies | Region- and time-dependent changes reported |
| BDNF protein | Rat brain studies | Increases reported under defined conditions |
| TrkB phosphorylation | Rat hippocampal experiments | Signalling changes reported |
| NGF expression | Cell and animal studies | Responses vary by brain region and timing |
| Specific binding sites | Rat brain membrane experiments | Binding demonstrated; full receptor identity unresolved |
| Cerebral ischaemia | Animal studies and limited clinical reports | Human treatment effectiveness remains uncertain |
| Learning and memory | Primarily animal experiments | General human cognitive benefit unestablished |
| Long-term human safety | Limited evidence | Inadequately characterised |
| US regulatory approval | FDA status | Not an approved medicine |
Semax Laboratory Testing: Identity, Purity and Stability
Reliable Semax research depends on the chemical identity and quality of the material used.
The sequence of seven amino acids should be verified rather than assumed from a product label.
Peptide Identity Testing
Mass spectrometry can provide evidence consistent with the expected molecular mass.
Additional analytical techniques may be needed to confirm sequence identity and distinguish related compounds.
HPLC Purity Testing
High-performance liquid chromatography can separate Semax from certain impurities under defined conditions.
A chromatographic purity percentage does not automatically establish absolute peptide content.
LC-MS Analysis
Liquid chromatography–mass spectrometry combines chromatographic separation with mass-based detection.
It can support identification of the intended peptide and selected related substances.
Methionine Oxidation
Semax contains methionine.
Methionine residues can be susceptible to oxidation under certain conditions.
Oxidation may alter the molecular mass and chemical properties of a peptide.
The extent of oxidation depends on the formulation and environmental conditions.
Why Degradation Matters
A degraded material may produce different experimental responses from the intended peptide.
Without suitable analysis, researchers may incorrectly attribute an observed effect to intact Semax.
Modified Analogues
N-acetyl Semax, amidated derivatives and other modified forms require separate identity specifications.
Analytical results from one derivative cannot automatically establish the properties of another.
Batch-Specific Certificates of Analysis
A Certificate of Analysis should identify the material and batch and report relevant analytical methods and results.
Sterility and Endotoxins
Peptide identity and chromatographic purity do not establish sterility or endotoxin status.
These are separate quality attributes.
Stability and Storage
Storage conditions should be supported by data applicable to the actual product format.
Generic statements about peptide stability cannot replace formulation-specific evidence.
Worked Example: Interpreting a Semax BDNF Experiment
Consider a hypothetical laboratory study measuring BDNF messenger RNA in cultured rat glial cells.
The experiment includes an untreated control and several experimental groups.
| Experimental condition | Hypothetical relative BDNF mRNA expression |
|---|---|
| Untreated control | 1.0 |
| Experimental group A | 1.8 |
| Experimental group B | 3.4 |
| Experimental group C | 2.1 |
These values are fictional and are provided solely to illustrate scientific interpretation.
What Does the Result Suggest?
The experimental groups show increased BDNF messenger RNA relative to the control.
Does This Prove Increased BDNF Protein?
No.
Protein measurements would be needed to determine whether the transcript changes correspond to altered BDNF protein levels.
Does This Prove Improved Memory?
No.
A cell-culture gene-expression assay cannot establish a behavioural or clinical outcome.
What Additional Experiments Would Help?
Complementary measurements could include BDNF protein quantification, TrkB phosphorylation, cell viability and independent replication.
Why Time Points Matter
Neurotrophin gene expression may change rapidly.
Measurements collected at different times can produce different results.
Main Lesson
A molecular response is useful evidence for a specific experimental question.
It should not be interpreted as proof of human cognitive enhancement.
Semax Compared With Selank and Other Neurological Research Peptides
Semax is often discussed alongside Selank and other neuroactive peptides.
However, their sequences and research histories differ.
| Compound | Molecular characteristic | Research distinction |
|---|---|---|
| Semax | ACTH-derived heptapeptide | BDNF, NGF and neurological signalling research |
| Selank | Tuftsin-derived heptapeptide | Experimental anxiety-related and immune-signalling research |
| KPV | Alpha-MSH-derived tripeptide | PepT1 transport and inflammatory signalling |
| MOTS-c | Mitochondrial DNA-encoded peptide | Metabolic stress and AMPK-associated pathways |
These compounds should not be treated as interchangeable.
Results from one peptide cannot establish the effects of another.
Likewise, studies of individual compounds do not establish the biological effects of peptide combinations.
Related Axion Peptide Lab Research Guides
Peptide Structure–Activity Relationships
Confirm that these planned internal article URLs are published before adding them as live links.
Semax Research Materials at Axion Peptide Lab
Axion Peptide Lab provides a catalogue of compounds relevant to laboratory and analytical research.
Researchers evaluating Semax should consult current product specifications and available batch documentation.
What Should Laboratories Verify?
Relevant specifications include the declared amino acid sequence, chemical form, nominal content, batch identification and analytical methods.
Why Is Sequence Verification Important?
Semax contains a defined seven-residue sequence.
A related fragment or modified analogue may have different chemical and biological properties.
Does High Purity Establish Neurotrophic Activity?
No.
Chromatographic purity does not independently establish a particular biological response.
Why Product Documentation Matters
Published experiments involve specific materials tested under defined conditions.
Their results do not automatically verify independently supplied research products.
Research-Only Distinction
Semax research materials should not be represented as FDA-approved medicines or as clinically validated cognitive enhancers.
Frequently Asked Questions About Semax Peptide Research
1. What is Semax peptide research?
Semax peptide research examines the synthetic ACTH-derived heptapeptide and its effects on neurotrophin gene expression, neurological signalling and experimental responses to brain injury.
2. What is the Semax amino acid sequence?
The conventional sequence is Met–Glu–His–Phe–Pro–Gly–Pro, abbreviated MEHFPGP.
3. Is Semax derived from ACTH?
Yes. Semax was developed from a modified ACTH(4–10) sequence.
4. Does Semax increase BDNF?
Selected rat studies have reported increased BDNF messenger RNA or protein under defined experimental conditions. The effects vary by brain region and timing.
5. Does Semax activate TrkB?
A rat hippocampal study reported increased TrkB phosphorylation. This does not establish Semax as a direct TrkB receptor agonist.
6. Does Semax affect NGF?
Yes. Experimental studies have reported changes in NGF gene expression, including region-specific increases and decreases.
7. Has Semax been studied for stroke?
Yes. Semax has been examined in animal models of cerebral ischaemia and in limited human clinical reports. Its effectiveness under contemporary US or UK clinical standards remains unestablished.
8. Is Semax proven to improve memory?
No. Animal behavioural studies provide experimental evidence, but strong clinical evidence demonstrating general cognitive enhancement in healthy humans is lacking.
9. Is Semax FDA-approved?
No. Semax is not an FDA-approved medicine in the United States.
10. How can laboratories verify Semax quality?
Relevant analytical approaches include HPLC, LC-MS, sequence-related identity testing, degradation assessment and batch-specific documentation.
Conclusion: What Semax Peptide Research Establishes
Semax peptide research has contributed to the scientific understanding of how ACTH-derived peptide sequences can influence neurological signalling.
Laboratory and animal studies have reported changes in BDNF, NGF, TrkB phosphorylation and brain-region-specific gene expression.
Additional experiments have examined Semax in models of cerebral ischaemia and learning-related behaviour.
These findings support continued research into neurotrophin regulation and peptide-associated cellular responses.
However, the evidence remains uneven.
The most detailed molecular findings come from preclinical models, while the human literature is limited by methodological and replication concerns.
Semax is not an FDA-approved medicine, and its clinical effectiveness as a cognitive enhancer or neurological treatment has not been adequately established.
For laboratories, accurate peptide identification, suitable analytical controls and careful interpretation of experimental findings remain essential.
Semax is a scientifically interesting ACTH-derived peptide, but changes in neurotrophin signalling should not be confused with demonstrated human therapeutic benefit.
Scientific References
- Shadrina MI, Dolotov OV, Grivennikov IA, et al. (2001). Rapid induction of neurotrophin mRNAs in rat glial cell cultures by Semax, an adrenocorticotropic hormone analogue. Neuroscience Letters, 308(2), 115–118.
https://pubmed.ncbi.nlm.nih.gov/11457573/ - Dolotov OV, Karpenko EA, Seredenina TS, et al. (2006). Semax, an analogue of adrenocorticotropin (4–10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain. Journal of Neurochemistry, 97(Suppl. 1), 82–86.
https://doi.org/10.1111/j.1471-4159.2006.03658.x - Dolotov OV, Karpenko EA, Inozemtseva LS, et al. (2006). Semax, an analog of ACTH(4–10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Research, 1117(1), 54–60.
https://doi.org/10.1016/j.brainres.2006.07.108 - Neurotrophin gene expression in rat brain under the action of Semax, an analogue of ACTH(4–10). (2007). Neuroscience Letters.
https://pubmed.ncbi.nlm.nih.gov/17353092/ - Effect of Semax on the temporal dynamics of brain-derived neurotrophic factor and nerve growth factor gene expression in the rat hippocampus and frontal cortex. (2008).
https://pubmed.ncbi.nlm.nih.gov/18756821/ - Comparison of the temporal dynamics of NGF and BDNF gene expression in rat hippocampus, frontal cortex and retina under Semax action. (2009).
https://pubmed.ncbi.nlm.nih.gov/19662538/ - United States Food and Drug Administration. (2026). Pharmacy Compounding Advisory Committee: Semax Scientific Review.
https://www.fda.gov/media/193348/download - United States Food and Drug Administration. (2026). Pharmacy Compounding Advisory Committee: Semax Nonclinical Pharmacology and Evidence Review.
https://www.fda.gov/media/193774/download - PubMed. Biomedical literature on Semax and ACTH-derived peptide research.
https://pubmed.ncbi.nlm.nih.gov/?term=Semax
These references support the discussion of published scientific findings. They do not verify the identity, purity, safety or clinical suitability of independently supplied research materials.
Research-use notice: This article is provided for scientific education and legitimate laboratory research. Axion Peptide Lab research materials are not intended for human or veterinary administration. Experimental findings and historical clinical reports should not be interpreted as medical advice, administration guidance or established claims of human therapeutic benefit.